Please Wait...

Development and Characterization of Two Polyclonal Antibodies Directed Against Human Periostin

Vergnaud P1, Pagnon-Minot A 2, Bertholon C 3, Lhoste Y1, Chassaing E1, Borel O 3, 4, Gineyts E 3, Schubert T 1, Clézardin P 3, Chapurlat R 3, 4, Rousseau JCh 3

 

1Bioclinica LAB, Lyon, France; 2 Novotec, Lyon, France; 3INSERM Unit 1033 and University of Lyon, Lyon,  France; 4 Hospices Civils de Lyon, Lyon, France

 

INTRODUCTION
Matricellular protein periostin (PN) is mainly expressed in the periosteum. PN regulates Notch1 signaling, activates lysyl-oxydase and mediates cancer cell adhesion, survival and invasion in different tissues. The aim of this study was to develop two polyclonal antibodies against the Fas-1 region of human PN and determine their specificity in human serum and bone tissue specimens.

 

 

METHODS
In silico analysis of the total protein sequence of human PN led us to identify two amino acid sequences that are suitable for antibody generation (Patent n° 13/375870) in the second and fourth Fasciclin-like domains [ETLEGNTIEIGCDGDSI (Ab-34) and KGFEPGVTNILKTTQGSK (Ab-12), respectively]. These two peptides were injected in rabbits following a standard protocol of 10 weeks of immunization. Specific polyclonal antibodies Ab12 and Ab34 were purified by immunoaffinity chromatography. We assessed the specificity of these antibodies for PN by immunohistochemistry (IHC) and western blotting (WB) using, respectively, human bone tissue and human sera previously depleted for albumin, IgG and transferrin.

 

RESULTS
Localization of antibody epitopes (Patent n° 13/375870).

  •  Ab12: Rabbit-polyclonal antibody against 575KGFEPGVTNILKTTQGSK592 sequence of human PN.
  •  Ab34: Rabbit-polyclonal antibody against 322ETLEGNTIEIGCDGDSI338  sequence of human PN.

 

WB analysis with Ab12 and Ab34 antibodies.

  •  Ab12 antibody recognizes two bands around 200 and 75 kDa in serum.
  •  After treatment by dithiothreitol (DTT) to reduce disulfide bonds, these bands disappear and 3 new bands are detected at 70, 50 and 25 kDa.
  • Ab34 recognizes a single band at 75 kDa in the serum.
  •  After DTT reduction, this band migrates at a molecular weight of 100 kDa, indicating that the reduction of intra-disulfide bonds in PN leads to a more extended conformation of the molecule and makes it run more slowly in the gel.
  • In SDS-Page gels the recognition of human recombinant PN is better with Ab12 than Ab34 antibodies.

 

IHC of human bone with Ab12 and Ab34 antibodies.

  •  Ab12 antibody shows a cytoplasmic staining only. This labeling is present in osteoblasts lining cortical bone (1) and in those present in the Haversian canals (2).
  •  Ab34 antibody shows a matrix staining of the periosteum (3) and of the edge of Haversian canal (4).

 

CONCLUSION
We have generated two polyclonal antibodies against the Fas-like domains of human PN. Our preliminary results suggest that they bind at least two forms of PN molecules in the serum and bone.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

ASCPT 2018 Annual Meeting https://t.co/i0mjYbBq5N Join @Bioclinica Research's Open House 3/22 https://t.co/citlLotbD7
bioclinica (2 days ago)
Heading to DC for DIA's #Pharmacovigilance & Risk Mgmt Strategies Conf.? Visit @Bioclinica in booth 32. Preview our… https://t.co/alU1sCg04l
bioclinica (2 days ago)
Kevin Bishop, named a 'Top Innovator' in #clinicaltrials by @CenterWatch See how we're reducing risk to the clinic… https://t.co/rXBGvIh9Wr
bioclinica (3 days ago)
RT @CenterWatch: Congratulations to all our #2018TopInovators! Read about the innovations in the #CWMonthly special edition, https://t.co/Y…
bioclinica (2 weeks ago)
RT @CenterWatch: .@Pfizer demonstrates leadership in #clinicaltrial innovation with two spots on the @CenterWatch #2018TopInnovators, https…
bioclinica (2 weeks ago)
RT @jheanne: I just contributed towards 'Joby' on https://t.co/EHt69JFLZ9 Best wishes to Joby and all our @Bioclinica team members! @Oxfam…
bioclinica (2 weeks ago)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen